On October 15, 2026, the American College of Obstetricians and Gynecologists (ACOG) published its first major update on menopause symptom treatment in more than a decade. The headline: hormone therapy now carries a strong recommendation for hot flashes, night sweats, and the sleep problems they cause, for women without a medical reason to avoid it. Here’s what changed, what didn’t, and what it means if you’re in Denver, Centennial, Alamosa, or anywhere in Colorado.
What ACOG published
The new document is ACOG Clinical Practice Guideline No. 13, Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms, published in Obstetrics & Gynecology. It replaces Practice Bulletin No. 141 from January 2014. In practical terms, the guideline most OB-GYNs in the country follow just caught up with more than ten years of newer research.
It applies to both perimenopausal and postmenopausal patients — so women who are still having periods but already dealing with hot flashes or broken sleep are covered too.
The key recommendations, in plain language
1. Hormone therapy is a first-line option for hot flashes and night sweats
For women without contraindications, ACOG now gives systemic hormone therapy a strong recommendation for vasomotor symptoms. It also gives a strong recommendation for hormone therapy to treat sleep problems driven by hot flashes — the 2 a.m. wake-ups that leave you exhausted the next day.
2. Timing matters
When hormone therapy is the right choice, ACOG strongly recommends starting before age 60 or within 10 years of menopause. Research reviewed for the guideline linked starting in that window with lower coronary heart disease risk, while starting more than 10 years after menopause was linked to higher blood clot and stroke risk. This is one of the clearest messages in the document: waiting years to “see if it passes” can narrow your options.
3. The right combination depends on your body
- If you have a uterus: estrogen plus a progestogen, to protect the uterine lining.
- If you’ve had a hysterectomy: estrogen alone.
In a network analysis the guideline cites, transdermal estradiol (delivered through the skin) with a progestogen ranked most effective for reducing hot flash frequency, and estradiol showed the largest effects on sleep.
4. Strong non-hormonal options for women who can’t or don’t want hormones
ACOG gives a strong recommendation to SSRIs, SNRIs, and the newer neurokinin receptor antagonists (fezolinetant and elinzanetant) for women who can’t take hormones or prefer not to. Those newer drugs require liver monitoring. Gabapentin is a conditional option, and CBT, mindfulness, exercise, and clinical hypnosis get conditional support, usually alongside medication.
5. Supplements didn’t make the cut
The guideline found that evidence does not support soy isoflavones or herbal supplements for hot flashes — on either effectiveness or safety. If you’ve spent months on a “menopause support” supplement with little change, that’s consistent with the evidence.
What about mood? ACOG found the evidence insufficient to recommend for or against hormone therapy specifically for menopause-related depressive symptoms. Women with significant depression should be treated under depression guidelines. In real life, mood often improves when sleep and hot flashes improve — but ACOG is clear that hormones aren’t a substitute for treating depression directly.
What the guideline doesn’t change
- Hormone therapy still isn’t for everyone. A history of blood clots, stroke, liver disease, or breast or other estrogen-sensitive cancers are reasons to avoid systemic estrogen. A real evaluation still comes first.
- Vaginal and urinary symptoms are getting their own guidance. ACOG says separate recommendations on genitourinary syndrome of menopause are expected in 2027.
- It’s a decision, not a default. The guideline supports offering hormone therapy — it doesn’t say every woman should take it.
Why this matters if you’ve been told to “wait it out”
For two decades, fear left over from the 2002 Women’s Health Initiative study kept many women from being offered treatment. ACOG’s update reflects what newer analyses have shown: nearly two-thirds of WHI participants were 60 or older, so its early headlines didn’t describe the risk for a typical woman in her 40s or 50s starting therapy near menopause.
This builds on the 2026 FDA labeling update that removed the boxed warning from menopausal hormone therapy products, which we covered in what the HRT black box removal means for you. Together, the message from regulators and specialists now points the same direction.
How we apply it at Defiance Health
Our approach already lines up with the new guidance. Our providers are WorldLink ABHRT certified, and every hormone plan starts with a comprehensive evaluation — not a symptom quiz.
- A full baseline panel. Estradiol, progesterone, FSH, LH, testosterone, DHEA-S, thyroid, cortisol, and metabolic markers, drawn in-office.
- Bioidentical options, matched to you. Estradiol and progesterone in the form that fits your history and preferences — including the transdermal route the guideline highlights.
- Honest screening for contraindications. If hormones aren’t safe for you, we’ll say so and talk through the non-hormonal options ACOG recommends.
- Follow-up that adjusts. Labs and symptom check-ins after you start, so your plan changes as your body does.
The comprehensive intake is $495 and includes your in-office lab draw, a full hormone panel, and a 60–75 minute provider visit. Learn more about our menopause care and perimenopause treatment.
Menopause care in Centennial, Alamosa, and by telehealth
Our Centennial clinic serves women across the south Denver metro, including the Denver Tech Center, Greenwood Village, Lone Tree, Highlands Ranch, Littleton, Parker, and Castle Rock. Our Alamosa clinic serves the San Luis Valley, including Monte Vista, Del Norte, and La Jara. Follow-up care is available by telehealth in Colorado, Arizona, California, and Washington.
Frequently asked questions
What did ACOG change about menopause hormone therapy in 2026?
ACOG Clinical Practice Guideline No. 13, published October 15, 2026, gives systemic hormone therapy a strong recommendation for hot flashes, night sweats, and related sleep problems in women without contraindications. It replaces guidance from 2014.
Is there an age limit for starting hormone therapy?
ACOG strongly recommends starting before age 60 or within 10 years of menopause onset when hormone therapy is chosen. Starting later is linked to higher blood clot and stroke risk, so timing is worth discussing with a provider sooner rather than later.
Does the guideline apply to perimenopause?
Yes. The guideline covers both perimenopausal and postmenopausal patients with vasomotor, sleep, or mood symptoms.
What if I can’t take hormones?
ACOG strongly recommends SSRIs, SNRIs, or neurokinin receptor antagonists for women who can’t or prefer not to use hormones. Gabapentin, CBT, and other approaches are additional options.
How much does menopause care cost at Defiance Health?
The comprehensive intake is $495 and includes an in-office lab draw, a full hormone panel, and a 60–75 minute provider visit. Ongoing treatment is quoted at your visit based on your protocol, and follow-up labs are billed separately. We’re cash-pay and accept HSA/FSA.
Ready to talk through your options?
Book a comprehensive intake in Centennial or Alamosa. We’ll review your labs and symptoms and give you an honest recommendation — hormonal or not.
Explore Menopause CareThis article summarizes published clinical guidance for education and isn’t medical advice. Hormone therapy isn’t right for everyone; treatment decisions are made with your provider after evaluation. — Jessica Lara, PA-C, Defiance Health